KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Enterprise Value (2016 - 2026)

Bio-Rad Laboratories has reported Enterprise Value over the past 18 years, most recently at -$1.6 billion for Q1 2026.

  • Quarterly Enterprise Value rose 5.76% to -$1.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.6 billion through Mar 2026, up 5.76% year-over-year, with the annual reading at -$1.5 billion for FY2025, 7.44% up from the prior year.
  • Enterprise Value was -$1.6 billion for Q1 2026 at Bio-Rad Laboratories, down from -$1.5 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$409.4 million in Q4 2023 and troughed at -$2.1 billion in Q1 2022.
  • The 5-year median for Enterprise Value is -$1.4 billion (2025), against an average of -$1.1 billion.
  • Year-over-year, Enterprise Value soared 77.35% in 2023 and then plummeted 306.57% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$439.8 million in 2022, then increased by 6.91% to -$409.4 million in 2023, then plummeted by 306.57% to -$1.7 billion in 2024, then increased by 7.44% to -$1.5 billion in 2025, then fell by 1.56% to -$1.6 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Enterprise Value are -$1.6 billion (Q1 2026), -$1.5 billion (Q4 2025), and -$1.4 billion (Q3 2025).